Credit Suisse Ag Lyell Immunopharma, Inc. Transaction History
Credit Suisse Ag
- $101 Billion
- Q1 2024
A detailed history of Credit Suisse Ag transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 123,256 shares of LYEL stock, worth $1.62 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
123,256
Previous 116,220
6.05%
Holding current value
$1.62 Million
Previous $225,000
21.78%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding LYEL
# of Institutions
15Shares Held
39.4MCall Options Held
0Put Options Held
0-
Apoletto LTD Washington, DC15.1MShares$198 Million42.56% of portfolio
-
Black Rock Inc. New York, NY13.5MShares$177 Million0.0% of portfolio
-
Wu Xi App Tec Co., Ltd. Shanghai, F47.39MShares$97 Million53.56% of portfolio
-
Mwg Management Ltd. Washington, DC1.01MShares$13.2 Million17.17% of portfolio
-
Orland Properties LTD Washington, DC755KShares$9.91 Million2.83% of portfolio
About Lyell Immunopharma, Inc.
- Ticker LYEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 247,824,992
- Market Cap $3.25B
- Description
- Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...